Latest news with #chronicDiseases
Health Line
02-07-2025
- Health
- Health Line
Is Vitamin E Useful for Treating Psoriasis?
Some studies have shown that vitamin E supplementation may be effective for psoriasis, but it is not currently recommended as a treatment method. More research is necessary to investigate its effectiveness. Psoriasis is a condition characterized by patches and scales that develop on the skin. These can also affect the scalp, nails, or joints, and can be itchy and painful. The patches can be red or pink, but may also appear purple on darker skin, while scales can be white, silvery, or even gray. Psoriasis is a chronic, long-term condition, and the symptoms can be different for everyone. Some people may have periods of remission when they're not experiencing any symptoms, followed by flare-ups when their usual symptoms can return and be quite intense. For some, psoriasis may be only a skin condition, but for others, it may also present with pain, tenderness, and swelling in their joints that may need additional treatment. This is called psoriatic arthritis. The article will look at the evidence for vitamin E as potential treatment or additional supplement for psoriasis and its effectiveness. Can vitamin E treat psoriasis? Vitamin E is a fat-soluble vitamin, which means your body can store it in its tissues and use it later when necessary. Your body uses vitamin E for multiple purposes, including supporting immune function and protecting against oxidative stress. This helps maintain healthy skin, eyes, and joints. In a 2021 study on chronic inflammatory diseases, researchers found that participants with vitiligo, psoriasis, or atopic dermatitis had lower levels of vitamin E than the participants in the control group who didn't have these conditions. They also discovered that supplementation with vitamin E showed significant improvement of oxidative stress markers in the participants with psoriasis and vitiligo. Researchers suspect this might be due to vitamin E's effect on antioxidant formation and lipid metabolism. However, more investigation is necessary on the exact mechanism of vitamin E levels in inflammatory skin diseases before this can be offered and recommended as a treatment. A 2024 study also concluded that higher antioxidant intake, particularly higher vitamin E levels, was associated with a lower likelihood of psoriasis. More research is still necessary to explore how targeted dietary interventions could help manage the condition. Research underscored the importance of nutrition and vitamin E intake for the management of psoriasis, but vitamin E supplementation is not currently a treatment method for the condition. While current research has shown some of its benefits, vitamin E is still not recommended as a long-term treatment. What are the treatment methods for psoriasis? Many topical treatments for psoriasis are available over the counter. These include: Coal tar shampoos, creams, ointments, or bath solutions: Coal tar can reduce redness, itching, and swelling. However, coal tar can also irritate the skin, so it's important to test it out first by applying it on a small patch of skin before covering any other areas affected by psoriasis. Hydrocortisone creams and ointments: These can reduce inflammation and itchiness. Ointments can be more soothing than creams on dry or cracked skin. Moisturizer: A daily moisturiser can seal in hydration and soothe the skin. It's important to choose a product that's appropriate for your skin and fragrance-free. Scale softeners: These can help reduce swelling and remove the scales. Try products with ingredients like salicylic acid, lactic acid, or urea to soften and remove the scales. Salicylic acid can sometimes be irritating on the skin, so use it according to instructions. Anti-itch products: Look out for products that contain the following ingredients to soothe the itch that may come with psoriasis: calamine camphor hydrocortisone menthol Other treatments for psoriasis include phototherapy or systemic treatments. Healthcare professionals usually prescribe these for moderate to severe psoriasis and for psoriatic arthritis. Reach out to a healthcare professional or dermatologist if you need more information about treatment methods for psoriasis and what would be most suitable for you. Takeaway Studies suggest a correlation between vitamin E levels and psoriasis. However, more research is necessary to investigate whether vitamin E can be a useful complementary therapy for the treatment of psoriasis. Plenty of treatments for psoriasis include topical therapies such as ointments and moisturisers that contain targeted ingredients such as coal tar or salicylic acid. Reach out to a dermatologist if you have questions or concerns about the condition.
Yahoo
25-06-2025
- Business
- Yahoo
Slide Stainers Market to Reach $5.53 Billion by 2032, Growing at a CAGR of 7.9% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Geriatric Population, Chronic Disease Burden, Laboratory Automation Demand, and Advanced Diagnostic Technology Integration REDDING, Calif., June 25, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Slide Stainers Market by Product (Reagents & Kits [Stains, Mounting, Tissue Fixation, Processing], Equipment), Technique (H&E, ISH, IHC, Hematology, Cytology), Application (Diagnosis, Research), End User (Hospitals & Diagnostic Centers, Pharmaceutical Companies, Academic Institutions) & Geography - Global Forecast to 2032", the Slide Stainers market is projected to reach $5.53 billion by 2032, growing at a robust CAGR of 7.9% during the forecast period. The substantial growth of the slide stainers market is driven by the rapidly aging global population coupled with the escalating burden of chronic diseases requiring precise diagnostic capabilities. The market's expansion is fueled by technological advancements in automated slide staining systems, increasing demand for personalized treatments, rising healthcare expenditure, and the critical need for automation in diagnostics and clinical research across leading healthcare institutions worldwide. The industry is experiencing revolutionary transformation through AI-powered staining protocols, enhanced automation capabilities, and development of multiplex staining technologies. Leading companies are embracing smart connectivity features while expanding into emerging markets and developing innovative automated slide staining solutions for accurate disease diagnosis and advanced research applications. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Diagnostic Automation Innovation The slide stainers market represents a paradigm shift in pathological diagnostics and histopathological research methodologies. As healthcare providers increasingly prioritize accuracy, consistency, and efficiency in disease diagnosis, automated slide stainers offer a revolutionary solution that addresses the growing demand for reliable, standardized tissue analysis procedures in modern laboratory environments. Market leaders are investing heavily in advanced robotic technologies and intelligent staining protocols, establishing manufacturing capabilities that can produce high-throughput, precision-engineered staining systems. This technological advancement is making automated slide stainers increasingly accessible while delivering superior diagnostic accuracy and operational efficiency benefits to pathology laboratories worldwide. Dynamic Growth Across Key Market Segments Based on products, the Reagents & Kits segment dominates the market in 2025, capturing the largest share due to the rising trend toward personalized medicine necessitating highly specialized reagents such as special stains, mounting reagents, and cytology stains for diagnostic tests. This segment benefits from the development of novel and innovative slide-staining reagents, including multiplex staining reagents that enable simultaneous detection of multiple biomarkers on a single slide. Based on technique categories, the Hematoxylin and Eosin (H&E) segment leads with the largest market share, reflecting its fundamental role as the most widely utilized staining procedure in pathology and histology. The advancement in H&E technology has resulted in more efficient and automated staining systems, making this technique more accessible to researchers and healthcare professionals globally. Based on End user, the Hospitals & Diagnostic Centers segment accounts for the largest share among end users, driven by the essential role of slide stainers in pathology, histology, and laboratory medicine for accurate disease diagnosis and treatment planning. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through AI integration in staining protocols, automation enhancement technologies, and expansion into personalized medicine applications. Companies are discovering new revenue streams through digital pathology integration and advanced biomarker detection capabilities while establishing comprehensive diagnostic solution ecosystems. Key market drivers include: Rising Geriatric Population: According to the United Nations, there were 727 million people aged 65 years or over globally in 2020, expected to increase to 1,548.9 million by 2050, driving demand for chronic disease diagnostics. Growing Chronic Disease Burden: WHO reports 41 million deaths due to chronic diseases in 2021 (74% of global deaths), with cardiovascular diseases (17.9 million), cancers (9.3 million), and chronic respiratory diseases (4.1 million) requiring advanced diagnostic capabilities. Cancer Incidence Growth: GLOBOCAN data shows 19.3 million cancer cases detected worldwide in 2020, expected to increase to 24.6 million by 2032, necessitating precision diagnostic tools. Laboratory Automation Demand: Increasing need for automated laboratory procedures for better diagnosis and reduced human error in critical pathological assessments Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025, driven by advanced healthcare infrastructure, high healthcare expenditure, established diagnostic laboratory networks, and strong adoption of automation technologies in pathology departments across leading medical institutions. Asia-Pacific emerges as the fastest-growing region, propelled by rising healthcare investments in emerging economies, increasing prevalence of chronic diseases, growing awareness of advanced diagnostic technologies, and expanding healthcare infrastructure in countries such as China, India, South Korea, and Singapore. Europe represents a significant market, supported by robust healthcare systems, strong research and development activities, and increasing government funding for cancer research and diagnostic advancement initiatives. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global slide stainers market features a sophisticated competitive ecosystem comprising established medical device manufacturers, specialized pathology equipment pioneers, and innovative technology companies. This diverse landscape fosters rapid technological advancement and comprehensive solution development. Industry leaders are implementing integrated automation solutions that combine advanced staining technologies with AI-powered analysis capabilities and comprehensive laboratory information management systems. Companies are pursuing strategic partnerships while addressing diagnostic accuracy and operational efficiency challenges across different healthcare market segments. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global slide stainers market include Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Abcam plc. (U.K.), Siemens Healthineers (Germany), General Data Company, Inc. (U.S.), Biocare Medical, LLC. (U.S.), BioGenex (U.S.), PHC Holdings Corporation (Japan), and Hardy Diagnostics (U.S.). Related Reports: Disinfection Robots Market Size, Share, Forecast, & Trends Antiviral & Antimicrobial Coatings Market Size & Share Point-of-care Diagnostics Market Size & Trends Analysis 2030 Viral Vaccines Market by Size, Share, Forecast, & Trends Analysis About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Sign in to access your portfolio
Yahoo
25-06-2025
- Business
- Yahoo
Slide Stainers Market to Reach $5.53 Billion by 2032, Growing at a CAGR of 7.9% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Geriatric Population, Chronic Disease Burden, Laboratory Automation Demand, and Advanced Diagnostic Technology Integration REDDING, Calif., June 25, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Slide Stainers Market by Product (Reagents & Kits [Stains, Mounting, Tissue Fixation, Processing], Equipment), Technique (H&E, ISH, IHC, Hematology, Cytology), Application (Diagnosis, Research), End User (Hospitals & Diagnostic Centers, Pharmaceutical Companies, Academic Institutions) & Geography - Global Forecast to 2032", the Slide Stainers market is projected to reach $5.53 billion by 2032, growing at a robust CAGR of 7.9% during the forecast period. The substantial growth of the slide stainers market is driven by the rapidly aging global population coupled with the escalating burden of chronic diseases requiring precise diagnostic capabilities. The market's expansion is fueled by technological advancements in automated slide staining systems, increasing demand for personalized treatments, rising healthcare expenditure, and the critical need for automation in diagnostics and clinical research across leading healthcare institutions worldwide. The industry is experiencing revolutionary transformation through AI-powered staining protocols, enhanced automation capabilities, and development of multiplex staining technologies. Leading companies are embracing smart connectivity features while expanding into emerging markets and developing innovative automated slide staining solutions for accurate disease diagnosis and advanced research applications. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Diagnostic Automation Innovation The slide stainers market represents a paradigm shift in pathological diagnostics and histopathological research methodologies. As healthcare providers increasingly prioritize accuracy, consistency, and efficiency in disease diagnosis, automated slide stainers offer a revolutionary solution that addresses the growing demand for reliable, standardized tissue analysis procedures in modern laboratory environments. Market leaders are investing heavily in advanced robotic technologies and intelligent staining protocols, establishing manufacturing capabilities that can produce high-throughput, precision-engineered staining systems. This technological advancement is making automated slide stainers increasingly accessible while delivering superior diagnostic accuracy and operational efficiency benefits to pathology laboratories worldwide. Dynamic Growth Across Key Market Segments Based on products, the Reagents & Kits segment dominates the market in 2025, capturing the largest share due to the rising trend toward personalized medicine necessitating highly specialized reagents such as special stains, mounting reagents, and cytology stains for diagnostic tests. This segment benefits from the development of novel and innovative slide-staining reagents, including multiplex staining reagents that enable simultaneous detection of multiple biomarkers on a single slide. Based on technique categories, the Hematoxylin and Eosin (H&E) segment leads with the largest market share, reflecting its fundamental role as the most widely utilized staining procedure in pathology and histology. The advancement in H&E technology has resulted in more efficient and automated staining systems, making this technique more accessible to researchers and healthcare professionals globally. Based on End user, the Hospitals & Diagnostic Centers segment accounts for the largest share among end users, driven by the essential role of slide stainers in pathology, histology, and laboratory medicine for accurate disease diagnosis and treatment planning. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through AI integration in staining protocols, automation enhancement technologies, and expansion into personalized medicine applications. Companies are discovering new revenue streams through digital pathology integration and advanced biomarker detection capabilities while establishing comprehensive diagnostic solution ecosystems. Key market drivers include: Rising Geriatric Population: According to the United Nations, there were 727 million people aged 65 years or over globally in 2020, expected to increase to 1,548.9 million by 2050, driving demand for chronic disease diagnostics. Growing Chronic Disease Burden: WHO reports 41 million deaths due to chronic diseases in 2021 (74% of global deaths), with cardiovascular diseases (17.9 million), cancers (9.3 million), and chronic respiratory diseases (4.1 million) requiring advanced diagnostic capabilities. Cancer Incidence Growth: GLOBOCAN data shows 19.3 million cancer cases detected worldwide in 2020, expected to increase to 24.6 million by 2032, necessitating precision diagnostic tools. Laboratory Automation Demand: Increasing need for automated laboratory procedures for better diagnosis and reduced human error in critical pathological assessments Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025, driven by advanced healthcare infrastructure, high healthcare expenditure, established diagnostic laboratory networks, and strong adoption of automation technologies in pathology departments across leading medical institutions. Asia-Pacific emerges as the fastest-growing region, propelled by rising healthcare investments in emerging economies, increasing prevalence of chronic diseases, growing awareness of advanced diagnostic technologies, and expanding healthcare infrastructure in countries such as China, India, South Korea, and Singapore. Europe represents a significant market, supported by robust healthcare systems, strong research and development activities, and increasing government funding for cancer research and diagnostic advancement initiatives. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global slide stainers market features a sophisticated competitive ecosystem comprising established medical device manufacturers, specialized pathology equipment pioneers, and innovative technology companies. This diverse landscape fosters rapid technological advancement and comprehensive solution development. Industry leaders are implementing integrated automation solutions that combine advanced staining technologies with AI-powered analysis capabilities and comprehensive laboratory information management systems. Companies are pursuing strategic partnerships while addressing diagnostic accuracy and operational efficiency challenges across different healthcare market segments. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global slide stainers market include Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Abcam plc. (U.K.), Siemens Healthineers (Germany), General Data Company, Inc. (U.S.), Biocare Medical, LLC. (U.S.), BioGenex (U.S.), PHC Holdings Corporation (Japan), and Hardy Diagnostics (U.S.). Related Reports: Disinfection Robots Market Size, Share, Forecast, & Trends Antiviral & Antimicrobial Coatings Market Size & Share Point-of-care Diagnostics Market Size & Trends Analysis 2030 Viral Vaccines Market by Size, Share, Forecast, & Trends Analysis About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
This new agreement marks the fourth product in the partnership and introduces a potential cost-effective alternative to one of the world's top-selling biologics—broadening access to specialty care for patients with chronic inflammatory diseases. The partnership further strengthens SteinCares' position as Latin America's leading one-stop-shop for biosimilars. GUANGZHOU, China and SAN JOSE, Costa Rica, June 25, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and SteinCares, a leading specialty healthcare company in Latin America, today announced the signing of a new agreement to commercialize a proposed biosimilar of dupilumab across Latin America. This is the fourth product that the two companies agree to collaborate and strengthens their shared commitment to improving access to high-quality, cost-effective therapies in the region. Under the agreement, Bio-Thera will be responsible for product development and supply, while SteinCares will lead the registration and commercialization process throughout Latin America. "Expanding access to advanced therapies while making healthcare more affordable is central to our mission," said Mitchell Waserstein, Chief Executive Officer at SteinCares. "Through this collaboration, we are reinforcing our position as one of the region's most robust biosimilar platforms in Latin America, offering a broad portfolio and pipeline tailored to the needs of patients and health systems across the region." Dupilumab is one of the top five medicines globally in terms of annual sales value, so this biosimilar is a significant milestone in SteinCares' expansion. The new partnership will potentially support the treatment of chronic inflammatory conditions in both adults and children. "This collaboration underscores our continued trust in SteinCares as a regional partner with strong regulatory, commercial, and medical capabilities," said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. "By leveraging well-established commercial network of SteinCares, we aim to accelerate the delivery of safe, high-quality and affordable therapies to patients across Latin America." With a presence in over 30 countries, SteinCares continues to act as a bridge between global pharmaceutical innovation and Latin America's healthcare systems, helping to balance budgets, expand access and improve health outcomes for patients in the region. About Bio-Thera Solutions, Ltd. Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including five approved products: adalimumab, bevacizumab and bevifibatide citrate Injection in China, ustekinumab in the US, and tocilizumab and bevacizumab in the US and in EU. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera). About SteinCares SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars, plasma-derived therapies, and complex generics. With more than 40 years of healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a trusted partner for global pharmaceutical companies entering the region. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families, with a vision of expanding access to innovative and cost-effective treatments. Learn more at or follow us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This news release contains certain forward-looking statements relating to Bio-Thera Solutions and SteinCares. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the companies' current views with respect to future events that are based on what the companies believe are reasonable assumptions in view of information currently available to Bio-Thera Solutions and SteinCares and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions and SteinCares undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the companies' views or otherwise. Bio-Thera ContactsBio-Thera Solutions, Ltd.:Bert E. Thomas IV+1.410.627.1734bethomas@ View original content to download multimedia: SOURCE Bio-Thera Solutions, Ltd
News.com.au
16-06-2025
- Health
- News.com.au
Dr Boreham's Crucible: Sizing up the opportunity for ASX biotech Adherium
When it comes to medication adherence, humans are strange beasts in that they will go out of their way not to take crucial therapies in the manner intended. In the case of asthma and chronic obstructive pulmonary disease (COPD), 'puffer' compliance is notoriously low: a staggering 92% of asthma users either deploy a poor technique or don't use their inhalers at all. Children might spray the treatment like a perfume and not inhale it into the lungs. Or the medicine can end up in the back of the throat rather than the bellows. On the evidence to date, Adherium (ASX:ADR) claims its wrap-around connected Haile monitoring device has improved asthma compliance by 180% for kids and reduced 'severe exacerbations' in adults by 61%. 'Not being able to do one of the most fundamental things in life – breathing – is one of the worst things imaginable,' Adherium director Keven Gessner says. Avoiding the 'frog in boiling water' syndrome Gessner likens asthma episodes to a frog in boiling water, which doesn't feel the rising heat until it's too late and has croaked it. 'Sometimes asthma and COPD is like sitting in that boiling water, because you get so used to not feeling well that you slowly get sicker and sicker and you don't realise it's boiling until it's too late,' he says. Gessner says most asthma episodes are preventable, while COPD patients could lead much better lives with correct compliance. A fresh board appointee, the US-based Gessner has a day job at Pfizer, where he is vice president in areas related to digital and remote patient monitoring. Moulded by his own experience with family and friends, he was drawn to Adherium and its mission of improving monitoring for some of the world's 300 million asthma and 384 million COPD sufferers. Asthma self-help spurns new company Originally known as Nexus6, Adherium was founded in New Zealand 2001 by former Microsoft software engineer Garth Sutherland, with the remit of managing his own asthma. The initial product, the Smartinhaler, was used widely in clinical trials. In 2009, it won US Food and Drug Administration (FDA) clearance under the 510(k)-device pathway. Adherium debuted on the ASX on August 26, 2015, having raised $35 million at 50 cents apiece in the initial public offer. A foundation client, pharma company Astrazeneca, invested $3 million. In mid-2021 fellow ASX-listed respiratory diagnostics counterpart Respiri made a conditional takeover for Adherium, but the entreaty ran out of breath. The updated device, Hailie, won FDA 510(k) clearance in April 2024 and is approved for use with 15 different puffers. Initially, Adherium expected Astrazeneca would take the running on Hailie - but that was not to be. Instead, Adherium operates through key US partner channels. These include hospital groups, payors and hybrid care/payor organisations. Payment depends on whether Adherium or the partner oversees the ongoing monitoring. CE-Oh – they've gone Mr Sutherland led the company until June 2017, after which he was succeeded by Arik Anderson, Mike Motion and Rick Legleiter. Mr Legleiter stepped down in mid-January 2024 and on February 1 he was replaced with another US candidate, Dr Paul Mastoridis. In October 2024, the company said the board and Dr Mastoridis had been unable to agree on his employment terms and that Dr Mastoridis would leave in January 2025. Since then, the company has been in 'ongoing dialogue with Dr Mastoridis and his lawyers regarding his cessation of employment'. Curnock Cook is the interim CEO and the managing partner of long-term shareholder, Bioscience Managers US focus Adherium's Hailie device wraps around conventional puffers and sends digital information about actual flow rates into the lungs. This enables the device to predict medical episodes earlier and avoid hospitalisations. In 2022, Clinical evidence suggested Hailie had improved asthma compliance by 180% for kids and reduced "severe exacerbations" in adults by 61%. But to gain traction, physicians must be paid for their time and the company needs to get a decent cut as well. Adherium is focused on the US market, where a reimbursement breakthrough three years ago enables just that, with the company signing up partnerships covering one million asthma and COPD patients. All hail Hailie Hailie can be used with about 90% of the inhalers on the market, including Glaxosmithkline's Ellipta and Astrazeneca's Symbicort. The Bluetooth-enabled Hailies capture physiological data like inhalation flow rates and provide real-time feedback through a software application to both the patient and their doctor. It also knows whether the device has been shaken (primed). 'You can't fake our meds,' Gessner says. 'If you push it and it shoots out into the air, it senses there has been no inspiration. We make sure the patient it is using the medication correctly and getting the clinical benefit of the drug.' Crucially, Hailie can also detect whether the patient is losing their ability to inhale properly. With physician intervention, the device can rescue the 'frog' before hospitalisation stage. The company cites 50 peer review studies validating Hailie's efficacy. Partnering up The company operates by two structures, whereby it either oversees the monitoring itself or via a partner. The company has signed up Allergy Partners, the biggest US asthma medical group with 140 locations in 20 states, servicing 300,000 asthmatics. 'We recruit the patients and monitor them,' Gessner says. 'If needs be, we will call up the patient with permission from their GP.' The second example is a partnership with Intermountain Health, an 'integrated delivery network' with 33 hospitals and 85 clinics servicing 250,000 patients. 'They are also payors, so benefit from the fewer hospitalisations.' Intermountain currently has 730 patients on its program. The third is AMC Health, the biggest private US remote patient monitoring company with 100,000 patients on its books. To date, AMC Health has ordered 750 Hailies. Sizing up the opportunity From its modest base of 1200 patients at the end of March, Adherium has targeted coverage of 9000 by the end of 2025. Allergy Group is expected to sign-up 5000 patients, with Intermountain and AMC contributing 2000 each. Under a 2022 reimbursement breakthrough, Hailie was classed under a Centers for Medicare and Medicaid code, with private payors extending coverage in 2023. The code provides for a US$55 initial payment and US$50 for every 20 minutes of care time. This averages out around US$160 per patient per month Currently the physicians are pocketing US$109 per patient: 'revenue that didn't exist until we came along,' Curnock Cook says. The company believes this number can increase to US$120-130 per month. As for Adherium, it expects to pocket US$50-75 per month per patient when it does the onboarding and monitoring and US$30-35 per month when it doesn't. Curnock Cook says that with growing interest from payors, the company should have access to two million patients, but the company will take a conservative approach to growth. Propeller stops turning Resmed's experience with its acquired Propeller Health business highlights the difficulty of navigating the complex US health and reimbursement channels. Even sleep apnoea giant Resmed has mis-stepped, having acquired the Wisconsin-based digital therapeutics company Propeller for US$225 million in early 2019. Resmed has quietly absorbed Propeller into its software-as-a-service business and its website no longer refers to Propeller puffer compliance devices in its suite of products. Adherium contends that Resmed overlooked the importance of winning physicians' advocacy of the device. The Bluetooth-connected Propellers measured the number of times the puffer had been pumped, but not flow rates into the lung. 'It measured whether the button had been pressed, but the spray could go anywhere,' Gessner says. Finances and performance Adherium reported customer receipts of $771,000 in the March 2025 quarter, compared with $148,000 in the December 2024 stanza, with net operating cash outflows of $2.21 million, taking the deficit for the first nine months of the financial year to $8.68 million, and end-of-quarter cash of $684,000, compared with $387,000 at the end of December. The increase is explained by a $2.6 million convertible note issue, announced in mid-March. The raising was contributed to equally by Bioscience Managers and Trudell Medical, which is associated with director George Baran. In May, Adherium issued a further $900,000 convertible note, mainly to the same parties. The notes have a nine-month maturity with a 10% a year interest rate. In mid-March, the company said it was planning a capital raising and 'it is comfortable that it is able to do'. The Hailie devices are made in Thailand with components from Singapore, but management expects little impact from the Trump administration's tariff plans. Adherium shares have ranged between two cents (at various times, most recently late January) and the current lows. In late 2023, the company consolidated its shares on a one-for-15 basis, from a tad under five billion shares to around 333 million. Allowing for this, Adherium shares hit a five-year peak of 64 cents in August 2021. Wot about us? The lack of reimbursement means Hailie is not available in Australia, but Curnock Cook has urged the Federal Government to add Hailie to its Medicare urgent care clinics. The company is seeking Federal funding for a program to deliver the Hailie technology to about 5,000 people with severe asthma over three years, at ten of the urgent care clinics. '$10 million should do it,' Curnock Cook says. 'Why not use this Australian-based tech to do something serious?' Adherium says in the 2020-21 year, asthma patients present 56,600 times to emergency departments, with half of the subsequent hospitalisations relating to asthma. Dr Boreham's diagnosis Gessner says that given the complexity of the US healthcare maze, Adherium's network would take decades to replicate. He adds that no party loses with Hailie. 'Not only are we being paid, but the physicians are getting paid, and the payors can see they can save a ton of money by keeping patients out of hospital.' So, the big picture is robust. But investors could be excused for thinking the company has run out of breath, with the shares declining 65% over the last year. Or has Adherium gone beyond the speculative 'pimping the puffer' to deliver the goods, having spent $150 million to get to this point? 'We have been around for 13 years, but we are no longer the company we were even a year ago,' Curnock Cook says. 'By the middle of next year there will be no question as to whether we are a real business or not. The question is how big and how we manage the growth.' At a glance: ASX code: ADR Share price: 0.7 cents Shares on issue: 758,185,209 Market cap: $5.3 million Financials (March quarter 2025): customer receipts $771,000, cash outflows $2.21 million, cash on hand $684,000 (ahead of $900,000 convertible note raising in May) Chief executive: Jeremy Curnock Cook (interim)
